Oehrberg 1995

Methods	ALLOCATION CONCEALMENT: unclear BLINDING: at least one measure was assessed by an independent assessor blind to treatment allocation
Participants	DIAGNOSIS: DSM‐III‐R panic disorder with or without agoraphobia (64% reported moderate to severe agoraphobia) AGE: mean=37.4 years SEX: 76% women HISTORY: unspecified PSYCHIATRIC COMORBIDITY: Primary diagnosis of major depression, generalized anxiety disorder, schizophrenia, dementia, organic brain disease, alcohol or drug abuse, or concomitant treatment with psychotropics and anticoagulants were excluded. The baseline 17‐item HAM‐D had to be 14 or less. MEDICAL COMORBIDITY: ‐
Interventions	ACUTE PHASE: 12 weeks 1. paroxetine (40‐60 mg/d) + CBT (details not given) 2. placebo + CBT ACUTE PHASE CO‐INTERVENTION: Concomitant use of benzo was prohibited. The urine was screened. MAINTENANCE: ‐ MODE OF DISCONTINUATION: ‐ FOLLOW‐UP: ‐
Outcomes	RESPONSE: >=50% reduction in panic frequency REMISSION: "mildly ill" or less on CGI GLOBAL: ‐ PANIC ATTACK: panic frequency AGORAPHOBIA: ‐ GENERAL ANXIETY: Zung Anxiety Scale DEPRESSION: ‐ FUNCTIONING: ‐
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear